Frank Neumann

'Can't say no': Kite Phar­ma taps Frank Neu­mann as new head of clin­i­cal de­vel­op­ment

Kite Phar­ma hit a ma­jor land­mark in Ju­ly when it got a sec­ond FDA OK, cre­at­ing the first com­mer­cial CAR-T port­fo­lio. But a biotech’s work is nev­er done. Now it’s time to ex­pand — and the Gilead sub­sidiary has tapped a new glob­al head of clin­i­cal de­vel­op­ment to lead the charge.

“Kite was al­ways kind of on the hori­zon as the… dream job come true,” Frank Neu­mann told End­points News. “This is a po­si­tion (where) if you’re in­ter­est­ed in cell ther­a­py, if you’re in­ter­est­ed in mak­ing a big im­pact on pa­tients’ lives, you just can’t say no.”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.